CC-97540

Phase 2Small molecule

JJuno Therapeutics, Inc., a Bristol-Myers Squibb Company

CC-97540 is one of 126 small molecule programs targeting Vasculitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

125

Competitors

Pipeline

Status by Indication[3][1]

Indication

VasculitisActive, not recruiting

LymphomaActive, not recruiting

Autoimmune DiseaseActive, not recruiting

Multiple SclerosisActive, not recruiting

Lupus Erythematosus, SystemicRecruiting

VasculitisPhase 1/Phase 2

Active, not recruiting

LymphomaPhase 1

Active, not recruiting

Autoimmune DiseasePhase 1

Active, not recruiting

Multiple SclerosisPhase 1

Active, not recruiting

Lupus Erythematosus, SystemicPhase 2

Recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

CC-97540

JJuno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 2

1 2

Oncaspar

SServier

Preclinical

15 3

Velban

EEastern Cooperative Oncology Group

Preclinical

15 4

Norvir

AbbVie

Preclinical

1 5

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 6

Tafasitamab

Incyte

Preclinical

7 7

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 8

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 9

Nuvigil

NNuvo Research GmbH

Preclinical

1 10

Systemic Therapy

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Recruiting

Multiple Sclerosis

NCT06220201

Q3 2028

Phase 1Recruiting

Autoimmune Disease

NCT05869955

Q4 2029

Phase 1/2Not yet recruiting

Vasculitis

NCT07388277

Q2 2032

Phase 2Recruiting

Lupus Erythematosus, Systemic

NCT07015983

Clinical

Trials by Indication[1]

Vasculitis1 trial

CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis

Not yet recruiting·MMarcela V. Maus, M.D.,Ph.D.·Phase 1/2·NCT07388277·12 enrolled

Autoimmune Disease1 trial

A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)

Recruiting·JJuno Therapeutics, Inc., a Bristol-Myers Squibb Company·Phase 1·NCT05869955·270 enrolled

Lymphoma1 trial

A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT04231747·24 enrolled

Multiple Sclerosis1 trial

A Phase 1, Multicenter, Single-arm, Dose-escalation Study of CC-97540 (BMS-986353), CD19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, Evaluating Safety and Tolerability in Participants With Autoimmune Neurological Diseases: Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS), or Refractory Myasthenia Gravis (MG).

Recruiting·JJuno Therapeutics, Inc., a Bristol-Myers Squibb Company·Phase 1·NCT06220201·120 enrolled

Lupus Erythematosus, Systemic1 trial

A Phase 2, Multicenter, Open-Label Study of CC-97540 (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE (Including Lupus Nephritis) With Inadequate Response to Glucocorticoids and at Least 2 Immunosuppressants (Breakfree-SLE)

Recruiting·JJuno Therapeutics, Inc., a Bristol-Myers Squibb Company·Phase 2·NCT07015983·89 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for CC-97540. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CC-97540 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CC-97540. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Juno Therapeutics, Inc., a Bristol-Myers Squibb Company company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: JJuno Therapeutics, Inc., a Bristol-Myers Squibb Company

CC-97540

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q3 2028

Q4 2029

Q2 2032

Trials by Indication[1]

Vasculitis1 trial

Autoimmune Disease1 trial

Lymphoma1 trial

Multiple Sclerosis1 trial

Lupus Erythematosus, Systemic1 trial

References

Drug Info

Quick Facts

Related News